Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy.
The osmotic fragility of erythrocytes was studied in 24 patients receiving whole-body hyperthermia, with and without concomitant chemotherapy, for 2-4 hours as an adjuvant to chemotherapy for advanced metastatic disease. No alteration in osmotic fragility of erythrocytes was observed with whole-body hyperthermia.
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000628:therapy; D000328:Adult; D003110:Colonic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006358:Hot Temperature / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000097:blood / Q000188:drug therapy / Q000628:therapy; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000628:therapy; D009996:Osmotic Fragility; D012673:Semustine / Q000627:therapeutic use
D012673:Semustine; D004317:Doxorubicin